Abstract:Cardiovascular diseases are the leading cause of mortality worldwide and about 25% of cardiovascular deaths are due to disturbances in cardiac rhythm or "arrhythmias". Arrhythmias were traditionally treated with antiarrhythmic drugs, but increasing awareness of the risks of presently available antiarrhythmic agents has greatly limited their usefulness. Most common treatment algorithms still involve small molecule drugs, and antiarrhythmic agents with improved efficacy and safety are sorely needed. This paper reviews the model systems that are available for discovery and development of new antiarrhythmic drugs. We begin with a presentation of screening methods used to identify specific channel-interacting agents, with a particular emphasis on high-throughput screens. Traditional manual electrophysiological methods, automated electrophysiology, fluorescent dye methods, flux assays and radioligand binding assays are reviewed. We then discuss a variety of relevant arrhythmia models. Two models are widely used in testing for arrhythmogenic actions related to excess action potential prolongation, an important potential adverse effect of chemical entities affecting cardiac rhythm: the methoxamine-sensitized rabbit and the dog with chronic atrioventricular block. We then go on to review models used to assess potential antiarrhythmic actions. For ventricular arrhythmias, chemical induction methods, cardiac or neural electrical stimulation, ischaemic heart models and models of cardiac channelopathies can be used to identify effective antiarrhythmic agents. For atrial arrhythmias, potentially useful models include vagally-maintained atrial fibrillation, acute asphyxia with atrial burst-pacing, sterile pericarditis, Y-shaped atria surgical incisions, chronic atrial dilation models, atrial electrical remodelling due to sustained atrial tachycardia, heart failure-related atrial remodelling, and acute atrial ischaemia. It is hoped that the new technologies now available and the recently-developed models for arrhythmia-response assessment will permit the introduction of newer and more effective antiarrhythmic therapies in the near future.

The canine chronic atrioventricular block model in cardiovascular preclinical drug research

Mechanical Analysis of Congestive Heart Failure Caused by Bundle Branch Block Based on an Electromechanical Canine Heart Model

Neurostimulation as a Method of Treatment and a Preventive Measure in Canine Drug-Resistant Epilepsy: Current State and Future Prospects

Characterization of remodeling processes in the atria of atrioventricular block dogs: Utility as an early-stage atrial fibrillation model

Evaluation of the translation of multiple cardiovascular regulatory mechanisms in the anesthetized dog

Theoretical Investigation Of The Mechanism Of Heart Failure Using A Canine Ventricular Cell Model: Especially The Role Of Up-Regulated Camkii And Sr Ca2+ Leak

An effective conscious animal model of atrial fibrillation

Canine Model of Ischemia-Induced Ventricular Tachycardia

Animal models of arrhythmia: classic electrophysiology to genetically modified large animals

Mechanisms of Atrial Tachyarrhythmias Associated With Coronary Artery Occlusion in a Chronic Canine Model

Therapeutic advances in atrial fibrillation based on animal models

Anti‐arrhythmic investigations in large animal models of atrial fibrillation

Model systems for the discovery and development of antiarrhythmic drugs

Ventricular Arrhythmias in First Acute Myocardial Infarction: Epidemiology, Mechanisms, and Interventions in Large Animal Models

The ECG in cardiovascular-relevant animal models of electrophysiology

Animal models for atrial fibrillation: clinical insights and scientific opportunities

Evolution and pharmacological modulation of the arrhythmogenic wave dynamics in canine pulmonary vein model

Role of Small-Conductance Calcium-Activated Potassium Channels in Atrial Electrophysiology and Fibrillation in the Dog

Mathematical Models of Canine Right and Left Atria Cardiomyocytes

In Vivo Approaches to Understand Arrhythmogenic Cardiomyopathy: Perspectives on Animal Models

Research('s) Sweet Hearts: Experimental Biomedical Models of Diabetic Cardiomyopathy